Interpretation of Global Strategy for the
Diagnosis，Treatment，Management and Prevention of Chronic Obstructive Pulmonary Disease
2022 Report

doi:10.12114/j.issn.1007-9572.2022.01.302

Abstract

Abstract:

Global initiative for chronic obstructive lung disease (GOLD) 2022 report was released on November 15, 2021. In general, chronic obstructive pulmonary disease (COPD) diagnosis, assessment and individualized therapy are the same as GOLD 2021, with corresponding content added in ten aspects. The article introduces and interprets the new content.

Key words: Chronic obstructive pulmonary disease, Pulmonary function, Telerehabilitation, Comorbidity, COVID-19, Guidebooks, COPD

摘要：

慢性阻塞性肺疾病（慢阻肺）全球倡议（global initiative for chronic obstructive lung disease，GOLD）2022年修订版于2021-11-15发布，总体来说其对于慢阻肺的诊断、评估、个体化治疗与GOLD 2021相同，但在10个方面增加了相应内容。本文对新增内容进行简介和解读。

关键词: 慢性阻塞性肺疾病, 肺功能, 远程康复, 合并症, 新型冠状病毒肺炎, 指南, COPD

CLC Number:

R563.9

CHEN Yahong .

Interpretation of Global Strategy for the Diagnosis，Treatment，Management and Prevention of Chronic Obstructive Pulmonary Disease 2022 Report [J]. Chinese General Practice, 2022, 25(11): 1294-1304.

陈亚红. 2022年GOLD慢性阻塞性肺疾病诊断、治疗、管理及预防全球策略更新要点解读[J]. 中国全科医学, 2022, 25(11): 1294-1304. DOI: 10.12114/j.issn.1007-9572.2022.01.302.

References 51

[1]	Global strategy for the diagnosis，management and prevention of chronic obstructive pulmonary disease 2022 report[EB/OL]. （2021-11-15）. .
[2]	陈亚红，王辰. 2015年更新版GOLD慢性阻塞性肺疾病诊断、治疗和预防的全球策略简介[J]. 中国医学前沿杂志（电子版），2015，7（2）：34-39.
[3]	陈亚红. 2017年GOLD慢性阻塞性肺疾病诊断、治疗及预防的全球策略解读[J]. 中国医学前沿杂志（电子版），2017，9（1）：37-47. DOI：10.12037/YXQY.2017.01-06.
[4]	陈亚红. 2018年GOLD慢性阻塞性肺疾病诊断、治疗及预防全球策略解读[J]. 中国医学前沿杂志（电子版），2017，9（12）：21-33.
[5]	陈亚红. 2019年GOLD慢性阻塞性肺疾病诊断、治疗及预防全球策略解读[J]. 中国医学前沿杂志（电子版），2019，11（1）：1-14.
[6]	陈亚红. 2020年GOLD慢性阻塞性肺疾病诊断、治疗及预防全球策略解读[J]. 中国医学前沿杂志（电子版），2019，11（12）：32-50. DOI：10.12037/YXQY.2019.12-08.
[7]	陈亚红. 2021年GOLD慢性阻塞性肺疾病诊断、治疗及预防全球策略解读[J]. 中国医学前沿杂志（电子版），2021，13（1）：17-39.
[8]	GBD Chronic Respiratory Disease Collaborators. Prevalence and attributable health burden of chronic respiratory diseases，1990-2017：a systematic analysis for the Global Burden of Disease Study 2017[J]. Lancet Respir Med，2020，8（6）：585-596. DOI：10.1016/S2213-2600(20)30105-3.
[9]	MONTSERRAT-CAPDEVILA J，MARSAL J R，ORTEGA M，et al.Clinico-epidemiological characteristics of men and women with a new diagnosis of chronic obstructive pulmonary disease：a database（SIDIAP） study[J]. BMC Pulm Med，2021，21（1）：44. DOI：10.1186/s12890-021-01392-y.
[10]	FAN H H，WU F，LIU J，et al. Pulmonary tuberculosis as a risk factor for chronic obstructive pulmonary disease：a systematic review and meta-analysis[J]. Ann Transl Med，2021，9（5）：390. DOI：10.21037/ATM-20-4576.
[11]	CHERIAN M，JENSEN D，TAN W C，et al. Dyspnoea and symptom burden in mild-moderate COPD：the Canadian Cohort Obstructive Lung Disease Study[J]. ERJ Open Res，2021，7（2）：00960-02020. DOI：10.1183/23120541.00960-2020.
[12]	DU Q X，JIN J M，LIU X F，et al. Bronchiectasis as a comorbidity of chronic obstructive pulmonary disease：a systematic review and meta-analysis[J]. PLoS One，2016，11（3）：e0150532. DOI：10.1371/journal.pone.0150532.
[13]	NI Y M，SHI G C，YU Y C，et al. Clinical characteristics of patients with chronic obstructive pulmonary disease with comorbid bronchiectasis：a systemic review and meta-analysis[J]. Int J Chron Obstruct Pulmon Dis，2015，10：1465-1475. DOI：10.2147/COPD.S83910.
[14]	GOËRTZ Y M J，LOOIJMANS M，PRINS J B，et al. Fatigue in patients with chronic obstructive pulmonary disease：protocol of the Dutch multicentre，longitudinal，observational FAntasTIGUE study[J]. BMJ Open，2018，8（4）：e021745. DOI：10.1136/bmjopen-2018-021745.
[15]	BALASUBRAMANIAN A，MACINTYRE N R，HENDERSON R J，et al. Diffusing capacity of carbon monoxide in assessment of COPD[J]. Chest，2019，156（6）：1111-1119. DOI：10.1016/j.chest.2019.06.035.
[16]	DE-TORRES J P，O'DONNELL D E，MARÍN J M，et al. Clinical and prognostic impact of low diffusing capacity for carbon monoxide values in patients with global initiative for obstructive lung diseaseⅠ COPD[J]. Chest，2021，160（3）：872-878. DOI：10.1016/j.chest.2021.04.033.
[17]	CASANOVA C，GONZALEZ-DÁVILA E，MARTÍNEZ-GONZALEZ C，et al. Natural course of the diffusing capacity of the lungs for carbon monoxide in COPD：importance of sex[J]. Chest，2021，160（2）：481-490. DOI：10.1016/j.chest.2021.03.069.
[18]	CELLI B R，ANDERSON J A，COWANS N J，et al. Pharmacotherapy and lung function decline in patients with chronic obstructive pulmonary disease. A systematic review[J]. Am J Respir Crit Care Med，2021，203（6）：689-698. DOI：10.1164/rccm.202005-1854OC.
[19]	JENKINS C R，WEN F Q，MARTIN A，et al. The effect of low-dose corticosteroids and theophylline on the risk of acute exacerbations of COPD：the TASCS randomised controlled trial[J]. Eur Respir J，2021，57（6）：2003338. DOI：10.1183/13993003.03338-2020.
[20]	中华医学会呼吸病学分会慢性阻塞性肺疾病学组，中国医师协会呼吸医师分会慢性阻塞性肺疾病工作委员会. 慢性阻塞性肺疾病诊治指南（2021年修订版）[J]. 中华结核和呼吸杂志，2021，44（3）：170-205.
[21]	慢性阻塞性肺疾病糖皮质激素规范管理撰写组. 慢性阻塞性肺疾病糖皮质激素规范管理专家共识（2021版）[J]. 中华结核和呼吸杂志，2021，44（12）：1054-1063.
[22]	TAN W C，BOURBEAU J，NADEAU G，et al. High eosinophil counts predict decline in FEV1：results from the CanCOLD study[J]. Eur Respir J，2021，57（5）：2000838. DOI：10.1183/13993003.00838-2020.
[23]	PARK H Y，CHANG Y，KANG D，et al. Blood eosinophil counts and the development of obstructive lung disease：the Kangbuk Samsung Health Study[J]. Eur Respir J，2021，58（4）：2003823. DOI：10.1183/13993003.03823-2020.
[24]	LIPSON D A，CRIM C，CRINER G J，et al. Reduction in all-cause mortality with fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease[J]. Am J Respir Crit Care Med，2020，201（12）：1508-1516. DOI：10.1164/rccm.201911-2207OC.
[25]	MARTINEZ F J，RABE K F，FERGUSON G T，et al. Reduced all-cause mortality in the ETHOS trial of budesonide/glycopyrrolate/formoterol for chronic obstructive pulmonary disease. A randomized，double-blind，multicenter，parallel-group study[J]. Am J Respir Crit Care Med，2021，203（5）：553-564. DOI：10.1164/rccm.202006-2618OC.
[26]	FRANCIOSI A N，HOBBS B D，MCELVANEY O J，et al. Clarifying the risk of lung disease in SZ alpha-1 antitrypsin deficiency[J]. Am J Respir Crit Care Med，2020，202（1）：73-82. DOI：10.1164/rccm.202002-0262OC.
[27]	LINDENAUER P K，STEFAN M S，PEKOW P S，et al. Association between initiation of pulmonary rehabilitation after hospitalization for COPD and 1-year survival among medicare beneficiaries[J]. JAMA，2020，323（18）：1813-1823. DOI：10.1001/jama.2020.4437.
[28]	STONE P W，HICKMAN K，STEINER M C，et al. Predictors of pulmonary rehabilitation completion in the UK[J]. ERJ Open Res，2021，7（1）：00509-02020. DOI：10.1183/23120541.00509-2020.
[29]	COX N S，DAL CORSO S，HANSEN H，et al. Telerehabilitation for chronic respiratory disease[J]. Cochrane Database Syst Rev，2021，1（1）：CD013040. DOI：10.1002/14651858.CD013040.pub2.
[30]	LIU X，FU C P，HU W P，et al. The effect of Tai Chi on the pulmonary rehabilitation of chronic obstructive pulmonary disease：a systematic review and meta-analysis[J]. Ann Palliat Med，2021，10（4）：3763-3782. DOI：10.21037/apm-20-940.
[31]	GOUZI F，MAURY J，HÉRAUD N，et al. Additional effects of nutritional antioxidant supplementation on peripheral muscle during pulmonary rehabilitation in COPD patients：a randomized controlled trial[J]. Oxid Med Cell Longev，2019，2019：5496346. DOI：10.1155/2019/5496346.
[32]	VAN BEERS M，RUTTEN-VAN MÖLKEN M P M H，VAN DE BOOL C，et al. Clinical outcome and cost-effectiveness of a 1-year nutritional intervention programme in COPD patients with low muscle mass：the randomized controlled NUTRAIN trial[J]. Clin Nutr，2020，39（2）：405-413. DOI：10.1016/j.clnu.2019.03.001.
[33]	BAFADHEL M，MCKENNA S，AGBETILE J，et al. Aspergillus fumigatus during stable state and exacerbations of COPD[J]. Eur Respir J，2014，43（1）：64-71. DOI：10.1183/09031936.00162912.
[34]	HUERTA A，SOLER N，ESPERATTI M，et al. Importance of Aspergillus spp. isolation in acute exacerbations of severe COPD：prevalence，factors and follow-up：the FUNGI-COPD study[J]. Respir Res，2014，15（1）：17. DOI：10.1186/1465-9921-15-17.
[35]	BULPA P，DUPLAQUET F，DIMOPOULOS G，et al. Invasive pulmonary aspergillosis in chronic obstructive pulmonary disease exacerbations[J]. Semin Respir Crit Care Med，2020，41（6）：851-861. DOI：10.1055/s-0040-1702210.
[36]	GU Y，YE X P，LIU Y X，et al. A risk-predictive model for invasive pulmonary aspergillosis in patients with acute exacerbation of chronic obstructive pulmonary disease[J]. Respir Res，2021，22：176.
[37]	COUTURAUD F，BERTOLETTI L，PASTRE J，et al. Prevalence of pulmonary embolism among patients with COPD hospitalized with acutely worsening respiratory symptoms[J]. JAMA，2021，325（1）：59-68. DOI：10.1001/jama.2020.23567.
[38]	FU C P，LIU X，ZHU Q Q，et al. Efficiency of high-flow nasal Cannula on pulmonary rehabilitation in COPD patients：a meta-analysis[J]. Biomed Res Int，2020，2020：7097243. DOI：10.1155/2020/7097243.
[39]	ALSALLAKH M A，SIVAKUMARAN S，KENNEDY S，et al. Impact of COVID-19 lockdown on the incidence and mortality of acute exacerbations of chronic obstructive pulmonary disease：national interrupted time series analyses for Scotland and Wales[J]. BMC Med，2021，19（1）：124. DOI：10.1186/s12916-021-02000-w.
[40]	CHAN K P F，MA T F，KWOK W C，et al. Significant reduction in hospital admissions for acute exacerbation of chronic obstructive pulmonary disease in Hong Kong during coronavirus disease 2019 pandemic[J]. Respir Med，2020，171：106085. DOI：10.1016/j.rmed.2020.106085.
[41]	US Preventive Services Task Force，KRIST A H，DAVIDSON K W，et al. Screening for lung cancer：US Preventive Services Task Force recommendation statement[J]. JAMA，2021，325（10）：962-970. DOI：10.1001/jama.2021.1117.
[42]	PARK H Y，KANG D，SHIN S H，et al. Chronic obstructive pulmonary disease and lung cancer incidence in never smokers：a cohort study[J]. Thorax，2020，75（6）：506-509. DOI：10.1136/thoraxjnl-2019-213732.
[43]	GE F，FENG Y，HUO Z Y，et al. Inhaled corticosteroids and risk of lung cancer among chronic obstructive pulmonary disease patients：a comprehensive analysis of nine prospective cohorts[J]. Transl Lung Cancer Res，2021，10（3）：1266-1276. DOI：10.21037/tlcr-20-1126.
[44]	RAYMAKERS A J，MCCORMICK N，MARRA C A，et al. Do inhaled corticosteroids protect against lung cancer in patients with COPD? A systematic review[J]. Respirology，2017，22（1）：61-70. DOI：10.1111/resp.12919.
[45]	WU M F，JIAN Z H，HUANG J Y，et al. Post-inhaled corticosteroid pulmonary tuberculosis and pneumonia increases lung cancer in patients with COPD[J]. BMC Cancer，2016，16（1）：778. DOI：10.1186/s12885-016-2838-4.
[46]	HIGHAM A，MATHIOUDAKIS A，VESTBO J，et al. COVID-19 and COPD：a narrative review of the basic science and clinical outcomes[J]. Eur Respir Rev，2020，29（158）：200199. DOI：10.1183/16000617.0199-2020.
[47]	MILNE S，LI X，YANG C X，et al. Inhaled corticosteroids downregulate SARS-CoV-2-related genes in COPD：results from a randomised controlled trial[J]. Eur Respir J，2021，58（1）：2100130. DOI：10.1183/13993003.00130-2021.
[48]	MUNBLIT D，BOBKOVA P，SPIRIDONOVA E，et al. Incidence and risk factors for persistent symptoms in adults previously hospitalized for COVID-19[J]. Clin Exp Allergy，2021，51（9）：1107-1120.
[49]	JONES R，DAVIS A，STANLEY B，et al. Risk predictors and symptom features of long COVID within a broad primary care patient population including both tested and untested patients[J]. Pragmat Obs Res，2021，12：93-104. DOI：10.2147/POR.S316186.
[50]	THOMPSON M G，EDWARD S，SHAUN G，et al. Effectiveness of COVID-19 vaccines in ambulatory and inpatient care settings[J]. N Engl J Med，2021，385（15）：1355-1371. DOI：10.1056/NEJMOA2110362.
[51]	MARTINEZ F J，AGUSTI A，CELLI B R，et al. Treatment trials in young patients with chronic obstructive pulmonary disease and pre-chronic obstructive pulmonary disease patients：time to move forward[J]. Am J Respir Crit Care Med，2022，205（3）：275-287. DOI：10.1164/rccm.202107-1663SO.

Interpretation of Global Strategy for the Diagnosis，Treatment，Management and Prevention of Chronic Obstructive Pulmonary Disease 2022 Report

2022年GOLD慢性阻塞性肺疾病诊断、治疗、管理及预防全球策略更新要点解读

RichHTML

PDF

Supplement

Knowledge

Abstract

Cite this article

share this article

References 51

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	CHEN Dian, LONG Huanyu, CHU Lanhe, JIANG Yixia, GUO Wanjin, NIU Yang, CHEN Yahong. Interpretation of Global Strategy for the Diagnosis, Treatment, Management and Prevention of Chronic Obstructive Pulmonary Disease 2026 Report [J]. Chinese General Practice, 2026, 29(21): 2913-2932.
[2]	ZHANG Wenbo, WANG Junlong, ZHANG Yuping, JIANG Shuai, WANG Huaqi. The Risk of Pre-COPD Populations Progressing to COPD under Different Criteria: a Meta-analysis [J]. Chinese General Practice, 2026, 29(19): 2735-2743.
[3]	CHEN Yiping, ZHANG Jianmei, LI Yanhu, LI Rui, ZHANG Ruiping, YANG Ping. Advances in the Diagnosis and Treatment of Post-COVID-19 Condition of Myocardial Injury [J]. Chinese General Practice, 2026, 29(18): 2585-2592.
[4]	ZHENG Zelu, ZHOU Jun, LIANG Zhi, WANG Xuehui, XU Feng, LI Oujing, XIAO Hong, LIU Xiaoyu, YANG Qingmei, ZHANG Mei, LIN Na, MI Baohong, CHEN Weiheng. Comorbidity Profiles and Treatment Patterns of Osteoarthritis Patients: a Cross-sectional Study Based on Community Medical Records [J]. Chinese General Practice, 2026, 29(16): 2205-2213.
[5]	XU Ping, MA Yan, HUANG Li, HE Meiliang, HOU Yunfeng, WANG Dewang, SUN Panpan, LIU Zheng, GUO Yanfang, XU Ying. Association between Weight-adjusted Waist Index and Comorbidity of Hypertension, Diabetes and Dyslipidemia in Community-dwelling Adults [J]. Chinese General Practice, 2026, 29(16): 2198-2204.
[6]	ZHAO Xuedan, AI Yue, JIN Guoen, JIA Guoqiang. The New Research Progress of Non-infectious Lung Diseases in High Altitude Areas [J]. Chinese General Practice, 2026, 29(14): 1931-1938.
[7]	YUAN Weixia, AO Panpan, MA Yun, WU Fengfu, XU Facui, YU Juan, ZENG Qun, WEI Shaofeng, YUAN Lijia. The Predictive Value of Age-adjusted Charlson Comorbidity Index for Sarcopenia in Older Adults [J]. Chinese General Practice, 2026, 29(13): 1673-1681.
[8]	SONG Lu, LAN Zhigang, ZHOU Wei, FENG Liping, LIU Yunqiu, CHEN Shuohua, WANG Liye. Correlation Study between Diabetes Mellitus and Lung Function in Male People [J]. Chinese General Practice, 2026, 29(12): 1572-1578.
[9]	YANG Fangting, XU Junfeng, YANG Qin, MA Yingzhi, ZHOU Ling, XIAO Jiangqin. Analysis of the Current Situation and Influencing Factors of Intolerance of Uncertainty in AECOPD Patients under the Perspective of Health Ecology [J]. Chinese General Practice, 2026, 29(11): 1434-1440.
[10]	GU Handong, LU Hongrun, GU Keyi, HAN Zheng, YANG Fei, FU Xiaoya, WANG Weiqiang. Association Research between Relative Fat Mass and the Incidence Risk of Cardiometabolic Multimorbidity [J]. Chinese General Practice, 2026, 29(11): 1456-1462.
[11]	SONG Lu, WANG Liye, XIU Chunxia, FENG Baojing, FENG Liping, GAO Yansong, LI Meng, DAI Yan. The Correlation Study of Pulmonary Function and Blood Pressure Variability in Patients with Chronic Obstructive Pulmonary Disease and Hypertension [J]. Chinese General Practice, 2026, 29(10): 1311-1315.
[12]	WANG Shuqi, MA Jun, WU Yunling, CHEN Fengfang, CHEN Xianqiu, YANG Wenlan, LI Qiuhong, HUANG Jin, FENG Yonghong. Differences in the Correlation of Serum ACE and sIL-2R with Pulmonary Function Parameters in Male and Female Patients with Newly Diagnosed Stage Ⅱ Sarcoidosis [J]. Chinese General Practice, 2026, 29(10): 1316-1323.
[13]	TIAN Ying, PAN Dianzhu. Analysis of Related Factors of Renal Function Impairment in AECOPD Patients [J]. Chinese General Practice, 2026, 29(07): 885-892.
[14]	XI Qian, SHEN Ying, ZHAO Can, JI Shuyu, PENG Houxuan, QIN Jinqiong, WANG Xuan, ZHENG Yanping, ZUO Yanli. Multimorbidity Patterns, Inpatient Care Utility, and Associated Factors in Inpatients with Multimorbidity in Township Health Centers [J]. Chinese General Practice, 2026, 29(04): 498-508.
[15]	CHEN Xueqin, WANG Shihong, LAI Fengxia, ZHANG Jingjing, CHEN Hao, KONG Danli, DING Yuanlin. Study on Trend Analysis and Forecast of Incidence, Disease and Mortality of Chronic Obstructive Pulmonary Disease in China, 1990-2021 [J]. Chinese General Practice, 2026, 29(02): 264-272.